Review
Copyright ©The Author(s) 2015.
World J Gastroenterol. Feb 14, 2015; 21(6): 1728-1737
Published online Feb 14, 2015. doi: 10.3748/wjg.v21.i6.1728
Figure 1
Figure 1 Number of inhabitants covered by one gastroenterology centre entitled to administer biological therapy in 9 selected Central and Eastern European countries, 2014. Population data: Eurostat Statistics Database (2013)[34], total health expenditure per capita (2012): World Bank Databank[26]. BGR: Bulgaria; CZE: Czech Republic; EST: Estonia; HUN: Hungary; LVA: Latvia; LTU: Lithuania; POL: Poland; ROM: Romania; SVK: Slovakia.
Figure 2
Figure 2 Average number of Crohn's disease patients treated with biologicals per 105 inhabitants compared to countries per capita total expenditure on health. Ulcerative colitis would display a similar figure. Sizes of bubbles refer to the absolute number of patients treated with biologicals in each country. Data sources: patient numbers: IMS data (2014 or latest available), population data: Eurostat Statistics Database (2013)[34], total health expenditure per capita (2012): World Bank Databank[26]. BGR: Bulgaria; CZE: Czech Republic; EST: Estonia; HUN: Hungary; LVA: Latvia; LTU: Lithuania; POL: Poland; ROM: Romania; SVK: Slovakia.